• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Does Guanfacine Affect Tic Severity in Children With Chronic Tic Disorders?

Does Guanfacine Affect Tic Severity in Children With Chronic Tic Disorders?

November 1, 2017
Arian Ayon Verduzco, Pharm.D candidate (2018)
From The Carlat Child Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Arian Ayon Verduzco, Pharm.D candidate (2018) Ms. Verduzco has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review Of: Murphy TK et al, J Child Adolesc Psychopharmacol 2017;20(20):1–9

Tic disorders, including Tourette’s, often co-occur with ADHD, OCD, and anxiety disorders. Guanfacine is often tried for all of these conditions. Randomized placebo-controlled trials of immediate release guanfacine have been mixed, with one showing 31% improvement in tics but another showing no significant improvement. Extended release (ER) guanfacine, while indicated for ADHD, has not been studied in children with tic disorders. Murphy et al set out to investigate its safety and efficacy as a treatment for chronic tic disorder (CTD).

This 8-week, double-blind, placebo-controlled trial included 34 subjects aged 6–17 years (mean 11 years), who met criteria for CTD. Children were either medication-free or on a stable OCD or anxiety regimen for at least 8 weeks. Participants were randomly assigned to either guanfacine ER (n = 16) or placebo (n = 18). Those in the medication group received a starting dose of 1 mg in the morning, which could be increased to as much as 4 mg per day and divided into two doses at the clinician’s discretion. Mean guanfacine ER dose was 2.6 mg. The primary outcome was change from baseline in the Yale Global Tic Severity Scale (YGTSS).

At 8 weeks, both groups had a few positive responders on the YGTSS; however, there was no significant difference between guanfacine ER (19%; 3/16) and placebo (22%; 4/18). Parent ratings of tic severity in the guanfacine group showed improvement, whereas no effect was seen with placebo. In addition, only the guanfacine group showed an improvement in ADHD symptoms. Common side effects in patients on guanfacine included fatigue, drowsiness, dry mouth, headache, irritability, stomachache, and decreased appetite.

CCPR’s Take
In this small pilot study, guanfacine ER was no more effective than placebo for improving symptoms in children with CTD. On the other hand, it did not worsen tics, which is reassuring, especially since stimulants can aggravate tics when used for ADHD. Guanfacine may have a place in treating ADHD specifically for children with tic disorder, with the modest goal of easing ADHD symptoms while at least not worsening tics.
Child Psychiatry
KEYWORDS ocd research_updates
    Arian Ayon Verduzco, Pharm.D candidate (2018)

    More from this author
    www.thecarlatreport.com
    Issue Date: November 1, 2017
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Adolescents, CCPR, November/December 2017
    Does Guanfacine Affect Tic Severity in Children With Chronic Tic Disorders?
    Does Methylphenidate Use in Children and Young Adults Increase Risk of Suicide?
    Tips on Managing Medications With Adolescents
    Understanding Risk-Taking in Adolescents
    DOWNLOAD NOW
    Featured Book
    • PB4e_Cover2.png

      Psychiatry Practice Boosters, Fourth Edition (2023)

      Teaches you the key points of 63 of the most clinically relevant studies in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.